Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 14, 2010

Sigma Life Science to Provide Oligonucleotides to Research Councils UK

  • Sigma Life Science signed a three-year contract with Research Councils UK (RCUK) Shared Services Centre to be a prefered supplier for synthetic oligonucleotides. With more than 20 years of experience in oligonucleotide synthesis, the company offers a broad, commercially available range of high-quality oligonucleotide modifications, purifications, synthesis scales, and qPCR probes. It has a U.K. production facility in Haverhill, near Cambridge.

    “Sigma Life Science has been a preferred oligonucleotide supplier to the Medical Research Council (one of the U.K.’s seven Research Councils) for over four years,” notes Michael Harris, managing director of Europe, Middle East, and Africa regions for Sigma-Aldrich. “This new agreement is expected to enable additional RCUK researchers to access Sigma’s products as well as allow Sigma Life Science to consolidate its relationship with RCUK.”

    Sigma Life Science provides a range of other molecular biology reagents including nucleic acid amplification and purification reagents, RNAi products like shRNAs, siRNAs, and ZFN technology, as well as more than 38,000 antibodies.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »